Company News

Strong Team - Four Senior Experts Join Gmax Biopharm


Gmax Biopharm is a clinical stage biopharmaceutical company focusing on the development of therapeutic antibody and Bibody of G protein-coupled receptors (GPCRs) to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer,etc. Recently the company announced that Dr. Xun Zhu and Dr. François Haddad joined company as science advisers, and Mr. James Philipson and Mr.Robert Lee, who are experts in marketing, investment and finance joined as business advisers. They will provide Gmax with scientific and strategic advisory on R&D, global multi-center clinical trials, international business development and IPO, etc.


With headquarters located at Hangzhou, China, GMAX has branches in the United States, Europe and Australia. Targeting to global market, its products are all orginally innovative and are being clinically developed in China and abroad followed by planned global commercialization.  The company has a rich and strategically developed pipeline with twenty-one antibody and Bibody drug candidates in different stages of R&D, including 8 Bibody candidates are in the pre-clinical stage, 2 candidates are in the clinical phase II stage and 1 finished phase I study heading to an international Multi-Center Trial.


The company leadership team believes that with the supports of the abudant experience and influence in the industry from the 4 advisors, the company will be moving much faster to bigger success.